AssetMark’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARQT
AssetMark's ARQT Position: Q3 2026 in Review
AssetMark increased its Arcutis Biotherapeutics (ARQT) stake by 0.25% in Q3 2026, buying an estimated $131 and bringing the position to 2,017 shares worth $53.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1860.
AssetMark first reported a position in ARQT in Q2 2022 and has held it in 18 quarters since. 220 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.
- AssetMark held 2,017 shares of Arcutis Biotherapeutics worth $53.3K as of Q3 2026.
- AssetMark bought 5 Arcutis Biotherapeutics shares in Q3 2026, an estimated $131.
- Arcutis Biotherapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1860 holding.
- AssetMark first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 18 quarters since.
- 220 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.